Determination of the 90% effective dose of Remimazolam for the endoscopy with general anaesthesia

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100045280

Enrollment

Unknown

Registered

2021-04-10

Start date

2021-04-12

Completion date

Unknown

Last updated

2021-11-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastrointestinal disease

Interventions

intravenous administration group:Remimazolam

intravenous continuous pumping group:Remimazolam

Eligibility

Sex/Gender

All

Age

1 Years to 9 Years

Inclusion criteria

Inclusion criteria: 1.Patients aged 1-9 years who need painless gastrointestinal endoscopy under non-tracheal intubation general anesthesia; 2.ASA (American Society of Anesthesiologists Physical Status Score) I-III level; 3.BMI 18-30 kg/m2.

Exclusion criteria

Exclusion criteria: 1.Patients who are known to be sensitive to benzodiazepines, flumazenil, opioids, naloxone or patients with contraindications; 2.Patients with difficult airway management, such as chin distance <= 4 cm or Mallampati scores of 3 or 4; 3.Patients with a history of sleep apnea.

Design outcomes

Primary

Measure	Time frame
Sedation score;	—

Countries

China

Contacts

Public ContactLi Bilian

Guangzhou Women and Children's Medical Centre

13570226780@126.com+86 13570226780

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026